Cargando…
Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C
BACKGROUND: Hepatocellular carcinoma (HCC) incidence and mortality vary by race/ethnicity and both are higher in Black patients than in Whites. For HCC surveillance, all cirrhotic patients are advised to undergo lifelong twice‐annual abdominal imaging. We investigated factors associated with surveil...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089228/ https://www.ncbi.nlm.nih.gov/pubmed/35261196 http://dx.doi.org/10.1002/cam4.4508 |
_version_ | 1784704476215508992 |
---|---|
author | Perumalswami, Ponni V. Wyatt, Brooke Bowman, Chip A. Patel, Krupa Mageras, Anna Lewis, Sara C. Branch, Andrea D. |
author_facet | Perumalswami, Ponni V. Wyatt, Brooke Bowman, Chip A. Patel, Krupa Mageras, Anna Lewis, Sara C. Branch, Andrea D. |
author_sort | Perumalswami, Ponni V. |
collection | PubMed |
description | BACKGROUND: Hepatocellular carcinoma (HCC) incidence and mortality vary by race/ethnicity and both are higher in Black patients than in Whites. For HCC surveillance, all cirrhotic patients are advised to undergo lifelong twice‐annual abdominal imaging. We investigated factors associated with surveillance and HCC incidence in a diverse HCC risk group, cirrhotic patients recently cured of hepatitis C virus (HCV) infection. METHODS: In this observational cohort study, all participants (n = 357) had advanced fibrosis/cirrhosis and were cured of HCV with antiviral treatment. None had Liver Imaging Reporting and Data System (LI‐RADS) 2–5 lesions prior to HCV cure. Ultrasound, computed tomography, and/or magnetic resonance imaging were used for surveillance. RESULTS: At a median follow‐up of 40 months [interquartile range (IQR) = 28–48], the median percentage of time up‐to‐date with surveillance was 49% (IQR) = 30%–71%. The likelihood of receiving a first surveillance examination was not significantly associated with race/ethnicity, but was higher for patients with more advanced cirrhosis, for example, bilirubin [odds ratio (OR) = 3.8/mg/dL, p = 0.002], private insurance (OR = 3.4, p = 0.006), and women (OR = 2.3, p = 0.008). The likelihood of receiving two or three examinations was significantly lower for non‐Hispanic Blacks and Hispanics versus non‐Hispanic Whites (OR = 0.39, and OR = 0.40, respectively, p < 0.005 for both) and for patients with higher platelet counts (OR = 0.99/10,000 cells/µl, p = 0.01), but higher for patients with private insurance (OR = 2.8, p < 0.001). Incident HCC was associated with higher bilirubin (OR = 1.7, p = 0.02) and lower lymphocyte counts (OR = 0.16, p = 0.01). CONCLUSIONS: Contrary to best practices, HCC surveillance was associated with sociodemographic factors (insurance status and race/ethnicity) among patients cured of HCV. Guideline‐concordant surveillance is needed to address healthcare disparities. |
format | Online Article Text |
id | pubmed-9089228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90892282022-05-16 Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C Perumalswami, Ponni V. Wyatt, Brooke Bowman, Chip A. Patel, Krupa Mageras, Anna Lewis, Sara C. Branch, Andrea D. Cancer Med Cancer Prevention BACKGROUND: Hepatocellular carcinoma (HCC) incidence and mortality vary by race/ethnicity and both are higher in Black patients than in Whites. For HCC surveillance, all cirrhotic patients are advised to undergo lifelong twice‐annual abdominal imaging. We investigated factors associated with surveillance and HCC incidence in a diverse HCC risk group, cirrhotic patients recently cured of hepatitis C virus (HCV) infection. METHODS: In this observational cohort study, all participants (n = 357) had advanced fibrosis/cirrhosis and were cured of HCV with antiviral treatment. None had Liver Imaging Reporting and Data System (LI‐RADS) 2–5 lesions prior to HCV cure. Ultrasound, computed tomography, and/or magnetic resonance imaging were used for surveillance. RESULTS: At a median follow‐up of 40 months [interquartile range (IQR) = 28–48], the median percentage of time up‐to‐date with surveillance was 49% (IQR) = 30%–71%. The likelihood of receiving a first surveillance examination was not significantly associated with race/ethnicity, but was higher for patients with more advanced cirrhosis, for example, bilirubin [odds ratio (OR) = 3.8/mg/dL, p = 0.002], private insurance (OR = 3.4, p = 0.006), and women (OR = 2.3, p = 0.008). The likelihood of receiving two or three examinations was significantly lower for non‐Hispanic Blacks and Hispanics versus non‐Hispanic Whites (OR = 0.39, and OR = 0.40, respectively, p < 0.005 for both) and for patients with higher platelet counts (OR = 0.99/10,000 cells/µl, p = 0.01), but higher for patients with private insurance (OR = 2.8, p < 0.001). Incident HCC was associated with higher bilirubin (OR = 1.7, p = 0.02) and lower lymphocyte counts (OR = 0.16, p = 0.01). CONCLUSIONS: Contrary to best practices, HCC surveillance was associated with sociodemographic factors (insurance status and race/ethnicity) among patients cured of HCV. Guideline‐concordant surveillance is needed to address healthcare disparities. John Wiley and Sons Inc. 2022-03-09 /pmc/articles/PMC9089228/ /pubmed/35261196 http://dx.doi.org/10.1002/cam4.4508 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Prevention Perumalswami, Ponni V. Wyatt, Brooke Bowman, Chip A. Patel, Krupa Mageras, Anna Lewis, Sara C. Branch, Andrea D. Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C |
title | Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C |
title_full | Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C |
title_fullStr | Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C |
title_full_unstemmed | Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C |
title_short | Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C |
title_sort | hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis c |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089228/ https://www.ncbi.nlm.nih.gov/pubmed/35261196 http://dx.doi.org/10.1002/cam4.4508 |
work_keys_str_mv | AT perumalswamiponniv hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc AT wyattbrooke hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc AT bowmanchipa hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc AT patelkrupa hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc AT magerasanna hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc AT lewissarac hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc AT branchandread hepatocellularcarcinomasurveillanceincidenceandtumordoublingtimesinpatientscuredofhepatitisc |